BRIEF—Rentschler Biopharma appoints new chief executive

Contract development and manufacturing organization (CDMO) Rentschler Biopharma has hired Benedikt von Braunmuehl as chief executive officer.

Formerly CEO of HMNC Brain Health, another German company, Mr von Braunmuehl has around three decades of experience in the industry, including at Qiagen, where he was head of global commercial operations.

Rentschler Biopharma has also appointed Tom Roberts as president and general manager of its US business. Mr Roberts has over 20 years’ experience in the industry, including at Vitanova Biomedical.

The company is ramping up its USA-based operations with a new facility, the Rentschler Biopharma Manufacturing Center.

Rentschler offers process development and manufacturing of biologics, including adeno-associated virus (AAV) gene therapies, as well as consulting services.